Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,422,658
  • Shares Outstanding, K 59,598
  • Annual Sales, $ 60,000 K
  • Annual Income, $ -78,960 K
  • EBIT $ 89 M
  • EBITDA $ 88 M
  • 60-Month Beta 2.17
  • Price/Sales 38.39
  • Price/Cash Flow N/A
  • Price/Book 4.28

Options Overview Details

View History
  • Implied Volatility 60.76% ( +3.89%)
  • Historical Volatility 41.49%
  • IV Percentile 33%
  • IV Rank 44.76%
  • IV High 103.32% on 10/04/24
  • IV Low 26.27% on 06/03/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 176
  • Volume Avg (30-Day) 170
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 5,017
  • Open Int (30-Day) 3,433

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.01
  • Number of Estimates 6
  • High Estimate 1.03
  • Low Estimate -0.57
  • Prior Year 0.44
  • Growth Rate Est. (year over year) -97.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.31 +22.67%
on 11/19/24
48.89 -16.42%
on 10/28/24
-5.10 (-11.10%)
since 10/21/24
3-Month
33.31 +22.67%
on 11/19/24
48.89 -16.42%
on 10/28/24
-0.69 (-1.66%)
since 08/21/24
52-Week
16.80 +143.21%
on 11/27/23
48.89 -16.42%
on 10/28/24
+23.50 (+135.37%)
since 11/21/23

Most Recent Stories

More News
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below

PTGX : 41.44 (+1.94%)
Protagonist Therapeutics: Q3 Earnings Snapshot

Protagonist Therapeutics: Q3 Earnings Snapshot

PTGX : 41.44 (+1.94%)
Protagonist Therapeutics: Q2 Earnings Snapshot

Protagonist Therapeutics: Q2 Earnings Snapshot

PTGX : 41.44 (+1.94%)
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal...

PTGX : 41.44 (+1.94%)
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

Stocks that traded heavily or had substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise

FCX : 43.75 (+0.11%)
PTCT : 43.06 (+2.62%)
ACCD : 3.68 (+3.37%)
KRUS : 94.43 (+5.95%)
PTGX : 41.44 (+1.94%)
INFN : 6.61 (unch)
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label...

PTGX : 41.44 (+1.94%)
Protagonist Therapeutics: Q1 Earnings Snapshot

Protagonist Therapeutics: Q1 Earnings Snapshot

PTGX : 41.44 (+1.94%)
Protagonist Therapeutics: Q4 Earnings Snapshot

Protagonist Therapeutics: Q4 Earnings Snapshot

PTGX : 41.44 (+1.94%)
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

NVS : 103.66 (+0.55%)
JNJ : 155.65 (+1.66%)
LEGN : 39.52 (-1.54%)
CVRX : 14.55 (+7.62%)
PTGX : 41.44 (+1.94%)
Protagonist Therapeutics: Q3 Earnings Snapshot

Protagonist Therapeutics: Q3 Earnings Snapshot

PTGX : 41.44 (+1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 45.34
2nd Resistance Point 43.26
1st Resistance Point 41.96
Last Price 41.44
1st Support Level 38.57
2nd Support Level 36.49
3rd Support Level 35.18

See More

52-Week High 48.89
Last Price 41.44
Fibonacci 61.8% 36.63
Fibonacci 50% 32.85
Fibonacci 38.2% 29.06
52-Week Low 16.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar